Page 1

IDEXX FOR IMMEDIATE RELEASE Contact : John Ravis , Investor Relations , 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results Achieves third quarter revenue growth of 12 % as reported and 10 % on an organic basis compared to high prior year growth levels Results driven by continued strong CAG business momentum , reflected in CAG Diagnostics recurring revenue growth of 13 % reported and 11.5 % organic and record Q3 global premium instrument placements Delivers EPS of $ 2.03 , representing 20 % growth as reported and 12 % on a comparable basis Updates 2021 guidance to higher end of previous guidance ranges , reflecting revenue growth outlook of 17.5 % - 18 % as reported and 15.5 % -16 % organic , and EPS growth of 24 % - 25 % as reported and 26 % - 27 % on a comparable basis WESTBROOK , Maine , November 2 , 2021- IDEXX Laboratories , Inc. ( NASDAQ : IDXX ) , a global leader in veterinary diagnostics , veterinary practice software and water microbiology testing , today announced third quarter results , as well as an update on U.S. companion animal diagnostics trends . Third Quarter Results The Company reports revenues of $ 810 million for the third quarter of 2021 , an increase of 12 % as reported and 10 % organically . Third quarter results were driven by Companion Animal Group ( " CAG " ) Diagnostics recurring revenue growth of 13 % reported and 11 % organic , with continued solid gains in the U.S. and internationally supporting two - year average annual reported revenue growth of 18 % and organic growth of 16 % . Overall revenue growth was also driven by 34 % reported and 33 % organic growth in CAG Diagnostics capital instrument revenue , and Water revenue growth of 15 % reported and 13 % organic . Earnings per diluted share ( " EPS " ) of $ 2.03 for the third quarter was supported by operating margin gains of 410 basis points on a reported basis , which benefited from lapping of a prior year $ 27.5 million accrual related to an ongoing litigation matter , and 20 basis points on a comparable basis , compared to high prior year levels which included benefits from pandemic - related cost controls . EPS results also benefited from $ 0.05 per share in tax benefits from share - based compensation . " The IDEXX team delivered another quarter of excellent performance , reflected in high CAG Diagnostics recurring revenue growth and record Q3 levels of premium instrument placements , with strong gains across our major in - clinic platforms , " said Jay Mazelsky , the Company's President and Chief Executive